Palantir stock faces hidden AI risk after Google deal

Palantir Technologies (PLTR) has spent years trying to convince Wall Street that it can become one of the most important software companies in the artificial intelligence boom.

Its most recent action does just that.

Palantir said on June 4 its software is available through the Google Cloud Marketplace, with interfaces connecting Google BigQuery, Gemini and Palantir's Artificial Intelligence Platform. The alliance provides Palantir another avenue into organizations that are already heavy spenders on cloud infrastructure, data systems and AI tools.

But as Palantir expands its commercial AI footprint, one of its biggest government contracts is becoming a political hotspot.

Reuters reported that the U.K. government is evaluating Palantir's £330 million contract with the National Health Service, under pressure to invoke a break provision attached to the pact.

That's not only a U.K. healthcare tale for American investors.

It's a test of whether Palantir can keep growing into sensitive data systems without provoking the kind of backlash that slows adoption, threatens contracts and undermines the premium valuation built into Palantir stock.

British lawmakers warned that the government's growing reliance on Palantir represents an "unacceptable point of weakness."

Palantir's Google Cloud deal gives AI a wider lane

Palantir's Google Cloud partnership comes at a critical time for the company.

The Denver software company is seeking to show that its artificial intelligence technologies aren't just for military, intelligence and government customers. Making Palantir available via Google Cloud Marketplace provides the company with another way into enterprise customers already using Google's cloud and data ecosystem.

This is important because Palantir's commercial business is growing fast.

Palantir said first-quarter revenue increased 85% to $1.63 billion from a year earlier. U.S. sales soared 104%, while U.S. commercial revenue soared 133% to $595 million.

The firm also boosted its full-year 2026 revenue guidance, providing investors more reason to think that Palantir is turning AI demand into real income, rather than just benefiting from the market's enthusiasm for the category.

That's the kind of numbers Palantir bulls want to see.

The company is not only marketing an AI tale. It is transforming demand into money, notably in the U.S. commercial market.

Related: Palantir challenges core enterprise software rule with 3 harsh words

The Google Cloud agreement is another chapter in that saga.

That shows Palantir is striving to make AIP easier to buy, easier to install and easier to link with solutions big enterprises currently use.

This is important because Palantir's valuation hinges on being able to prove its AI platform can extend much beyond its original, government-heavy customer base.

More AI:

• Micron sits at the center of a red-hot chip rally
• IBM CEO sends blunt message on AI and quantum computing
• Anthropic CEO makes shocking admission about AI

Palantir was last trading about $135, giving the business a market value of about $346 billion and a price-to-earnings ratio exceeding 151.

At that level, investors are not just buying good quarterly growth.

They're paying for the premise that Palantir can become key AI infrastructure in public and private markets.

Palantir's NHS backlash raises a harder investor question

The problem: Palantir's biggest prospects are frequently with the most sensitive data.

And that's why the NHS fight matters so much to investors outside the U.K.

The NHS contract to develop a platform for combining health-service data was granted in 2023. Reuters says the pact is valid until early 2027, when the government has to decide whether to renew it or activate a break provision.

The inquiry will consider patient confidentiality, public trust and reliance on a U.S. supplier, Reuters quoted Technology Minister Liz Kendall as saying.

That kind of scrutiny can be a concern for a corporation attempting to sell AI into hospitals, police departments, defense agencies and other sensitive public systems.

The criticism has also spilled out onto the streets.

On June 11, roughly 80 protesters gathered outside the NHS ConfedExpo in Manchester, according to WIRED. Protesters called for Palantir's removal from the health service and raised concerns about health data, national security, and the company's political associations.

Palantir has defended its collaboration with the NHS.

Palantir says its software has helped deliver 110,000 additional operations, cut discharge delays by 15%, and removed almost 800,000 patients from waiting lists.

That is why the discussion is so crucial.

Palantir's software could be useful in its ability to organize fragmented, sensitive data and turn it into operational decisions. But the further Palantir embeds itself in health care, defense, policing and public infrastructure, the greater the political scrutiny.

FABRICE COFFRINI / Getty Images

Palantir stock has little room for political missteps

The NHS dispute isn't about one British contract's magnitude for U.S. investors.

It is about the bigger growth model.

The stock is pricing in that Palantir can continue to convert AI demand to long-term commercial and government revenue. The Google Cloud agreement reinforces that notion, providing Palantir another avenue into enterprise AI investment.

The NHS backlash makes it more complex.

A business with Palantir's worth can't afford to give investors any reason to wonder whether resistance in the public sector will be a recurring impediment. This issue is especially relevant when Palantir's strongest prospects simultaneously risk raising concerns over privacy, sovereignty and vendor dependence.

And that risk is not hypothetical.

London Mayor Sadiq Khan also cancelled a £50 million Metropolitan Police deal with Palantir, citing concerns over value for money and whether firm ethics should be a consideration in public procurement.

That's a second data point for investors.

The NHS struggle may not be a debate in itself. That might be part of a broader pattern where Palantir's public sector work is exceptionally politically sensitive.

Momentum is still very much with Palantir.

It's seeing a surge in U.S. commercial revenue. Its connection with Google Cloud opens up a wider enterprise path. It remains good business for its government.

But the NHS battle reveals another aspect of the AI boom.

What makes Palantir interesting to institutions is the same thing that makes it politically sensitive.

The question for investors is no longer whether Palantir has demand.

That is clearly true.

The greater challenge is whether Palantir can scale into the world's most critical data systems without becoming so controversial that those systems stop utilizing it.

Related: Palantir CEO takes pointed shot at Anthropic

The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

This story was originally published June 16, 2026 at 11:17 AM.